Atlas Trials

An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis

Clinical trial NCT02407041 · COMPLETED

Trial details

NCT number
NCT02407041
Sponsor
Galectin Therapeutics Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Psoriasis
Start date
2015-09-01
Primary completion
2018-03-01
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.